Background. With the rapid rollout of antiretroviral therapy (ART) in sub-Saharan Africa (SSA), there has been an increasing concern about cardiovascular risks related to ART. However, data from human immunodeficiency virus (HIV)-infected populations from this region are very limited.
factors such as the use of less lipid-friendly ART agents [8] . With the expansion of ART coverage and the aging of the HIVinfected population, it becomes imperative to monitor cardiovascular risk, identify risk factors, and integrate prevention and treatment of cardiovascular disease into the HIV care and treatment in SSA.
Dyslipidemia is a well-known risk factor for cardiovascular disease, and it is common in HIV-infected patients. Both HIV infection and ART, particularly protease inhibitor-based regimens, and certain nucleoside reverse transcriptase inhibitors (NRTIs) such as stavudine (d4T), have been associated with lipid abnormalities [9] [10] [11] [12] [13] [14] . By the end of 2011, >8 million people living with HIV had access to ART in low-and middleincome countries [15] . However, to our knowledge, only 1 study has examined the longitudinal lipid changes among HIV-infected patients following ART initiation in SSA and the study findings were limited by the small sample size [16] . Using data from a large cohort of HIV-infected adults living in Dar es Salaam, Tanzania, we assessed changes in lipid profile after first-line ART initiation and the associations of different ART agents with these changes over a 3-year period.
METHODS

Study Population
This longitudinal observational study was conducted among HIV-infected patients attending HIV Care and Treatment clinics supported by the Management and Development for Health (MDH) HIV Care and Treatment program in Dar es Salaam, Tanzania, and the President's Emergency Plan for AIDS Relief (PEPFAR). Previously ART-naive, nonpregnant adult patients (≥15 years of age) who were initiated on ART and who had baseline and at least 1 follow-up lipid measures were included in this analysis. Antiretroviral drugs were provided free of charge by the Tanzanian government. Recommended first-line ART regimens at the time of this study included the combination of 2 NRTIs, d4T or zidovudine (AZT), along with lamivudine, and 1 nonnucleoside reverse transcriptase inhibitor (NNRTI), efavirenz (EFV) or nevirapine (NVP). The study was approved by institutional review boards for human research at the Harvard School of Public Health and at Muhimbili University of Health and Allied Sciences in Dar es Salaam, Tanzania.
Data Collection
Clinical care of HIV-infected patients at MDH-supported HIV care and treatment clinics follows national and World Health Organization (WHO) guidelines [17, 18] . Following ART initiation, patients are evaluated monthly. At each visit, they are examined by a physician, receive ART refills, and are provided adherence and nutrition counseling, if necessary. Physician and nurses complete standard forms capturing demographic, clinical, laboratory, and treatment-related information at baseline and follow-up visits. + cell counts from baseline (<100, 100 to <200, 200 to <300, ≥300 cells/µL), and months from ART initiation corresponding to changes in lipid outcomes.
Statistical Analysis
Generalized estimating equations [20] with an identity link function and an exchangeable working covariance structure were used to investigate the associations between different ART agents and changes in lipid parameters over time. Estimate statement in Proc Genmod were used to calculate the adjusted mean changes in lipid measure from baseline at 6, 12, 24, and 36 months of ART treatment. We ran separate model for each lipid outcome. Missing indicators were created and adjusted in the model for covariates with >1% missing. To take into account the selection bias in term of lipid measures, we also performed sensitivity analyses with the use of inverse probability of treatment weighted (IPTW) in which we weighted the study participants and their follow-up lipid measures by their inverse probabilities of being included into the study, death, and loss to follow-up during the 3-year follow-up period. All statistical analyses were performed with the statistical software package SAS (release 9.2). The significance tests were 2-sided, and differences were considered significant at P < .05.
RESULTS
The patient characteristics at ART initiation are shown in (Table 1) . At baseline, 69% patients had dyslipidemia, which was characterized predominantly by low HDL-c (55%) and elevated TG levels (26%). During follow-up, TG decreased from 127 mg/dL at baseline to 113 mg/dL at 6 months, then returned to and exceeded its baseline level to 139 mg/dL at 36 months. HDL-c increased from 39 mg/dL at baseline to 52 mg/dL at 6 months, then maintained at high levels afterward. TC and LDL-c continuously increased with TC increasing from 151 mg/dL at baseline to181 mg/dL at the end of follow-up, and LDL-c from 92 mg/dL to 111 mg/dL. The proportion of dyslipidemia dropped to 54% at 6 months due to increasing HDL-c and decreasing TG in the first 6 months of ART; thereafter the proportion of dyslipidemia gradually increased over time up to 73% at 36 months of ART (Table 2, Figure 1 ).
In multivariate analysis, patients on AZT-containing regimens had a greater reduction in TG levels at 6 months of ART (−16.0 vs −6.3 mg/dL), and a lower increase in TG at 36 months compared to patients on d4T-containing regimens (2.1 vs 11.7 mg/dL, P < .001; Table 3 ); Patients on NVP-based regimens had a 4.1 mg/dL higher increase in HDL-c levels at 36 months of ART compared to those on EFV-based regimens (13.6 vs 9.5 mg/dL, P = .01; Table 3 ). No associations were found between ART agents (d4T vs AZT, or EFV vs NVP) with changes in TC and LDL-c during the follow-up period (Table 3) . We observed similar results in the sensitivity analysis in which we took into account the possible selection bias in term of lipid measures by use of IPTW method. The differences between d4T and AZT regimens remained statistically significant with respect to changes in TG (P = .02). Although patients on NVP-based regimens were still observed with a mean 4.0 mg/dL higher increase in HDL-C compared to those on EFVbased regimens at 36 months of ART, it was no longer statistically significant (P = .26), possibly due to the larger variance resulting from the IPTW analysis.
Other factors associated with changes in lipid parameters in the 36 months following ART initiation are summarized in Table 4 . Older patients had greater increases in TG and TC. Men had a higher increase in TG compared to women. Patients with higher BMI at ART initiation baseline had a greater increase in TG and a lower increase in HDL-c at 36 months of ART. BMI changes after ART initiation were positively associated with increases in TC and HDL-c. Higher hemoglobin levels at baseline were associated with lower increases in TC, HDL-c, and LDL-c. Patients with a higher CD4 + cell counts at baseline had a greater increases in TG and HDL-c, and greater increases in CD4 + cell counts during the follow-up were associated with a greater increase in LDL-c. In addition, early WHO disease stage was associated with a greater increase in TG. Patients with elevated ALT levels (>40 U/L) had a greater increase in TC and LDL-c (Table 3) .
DISCUSSION
In this large cohort of HIV-infected adults in Dar es Salaam, Tanzania, we found that the high prevalence (69%) of dyslipidemia was characterized by low HDL-c and elevated TG concentrations, prior to ART initiation. After ART initiation, lipid abnormalities were improved temporarily then worsened gradually over a 3-year follow-up, with more unfavorable changes in patients on d4T and EFV-based regimens compared to AZT and NVP-based regimens. Studies have consistently found that compared to HIVuninfected controls, untreated HIV-infected individuals had higher concentrations of TG and lower concentrations of HDL-c [11, 21] . Our finding of the high prevalence of dyslipidemia among previously ART-naive patients at baseline is consistent with the results from other studies [16, 22] and our previous report [23] . It has been proposed that the HIVinfected immunosuppressed status is associated with high cytokine levels and heightened proinflammatory responses, which are related to increases in de novo lipogenesis and reduced very low-density lipoprotein clearance [24] .
Our results suggest that ART provides both benefits and risks for HIV-infected patients with respect to lipid profile. In the first several months of treatment, ART appears to return TG and HDL-c levels to normal. This correction in lipid profile is perhaps largely due to the suppression of viral replication and restoration of immune function following ART initiation, representing a return toward a less proinflammatory state and to preinfection serum lipid levels [25] . However, the benefit was not sustained. After 6 months, HDL-c levels stabilized whereas TC and LDL-c concentrations continued to increase. TG also increased, eventually exceeding its baseline level. Ultimately, the prevalence of dyslipidemia increased to 73% at 36 months of follow-up. Although the mechanisms are not well understood, many ART agents interfere with lipid metabolism [26] . Side effects of ART including lipodystrophy, insulin resistance, liver toxicity, and an upgraded inflammatory response resulting (6) 20 (4) 8 (4) 2 (7) 18.5 to <25 kg/m 2 13 (6) 15 (6) 9 (3) 2 (5) ≥25 kg/m 2 22 (6) 17 (5) 50 to <100 cells/µL 2 (7) 21 (4) 9 (3) 5 (6) 100 to <200 cells/µL 13 (6) 20 (4) 9 (3) 2 (5) ≥200 cells/µL 16 (6) 18 (4) 11 ( (6) 22 (5) 15 ( (6) 28 (5) 16 ( 100 to <200 cells/µL 8 (6) 23 (5) 9 (3) 8 (5) 200 to <300 cells/µL 8 (6) 22 (4) 9 (3) 5 (5) ≥300 cells/µL 9 (6) 20 (5) 7 (3) 6 (5) Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; HDL-c, high-density lipoprotein cholesterol; HIV, human immunodeficiency virus; LDL-c, lowdensity lipoprotein cholesterol; SE, standard error; TC, total cholesterol; TG, triglyceride; WHO, World Health Organization. a Adjusted for antiretroviral agents (stavudine vs zidovudine; and efavirenz vs nevirapine); all other independent variables in tables were mutually adjusted for.
from HIV infection might interplay together to further contribute to the development of dyslipidemia among HIV-infected patients on ART [7, 26] . Cardiovascular disease has been recognized as an increasing cause of morbidity and mortality among people living with HIV. In developed countries, it is the leading cause of death among HIV-infected individuals [27] . With the scaling up of ART in SSA, HIV-infected individuals are living longer in this region. It has been estimated that incidence of cardiovascular disease will increase dramatically in the coming decades in SSA, posing severe challenges to the current health system [2] . To meet the challenges, it is becoming imperative to monitor cardiovascular risk, identify risk factors associated with cardiovascular disease, and determine how these risks should best be managed in HIV-infected populations receiving ART. Given the investments that many HIV/AIDS treatment programs have made in strengthening health systems, additional efforts to integrate the prevention and care of cardiovascular disease should be considered in low-income countries [28] .
Most of the previous studies examining the effects of different ART on lipid levels have been conducted in developed countries [11, 13, 14, 29, 30] . Because monitoring of lipid levels during ART is rarely feasible in most healthcare facilities in SSA, data from the region are sparse. To our knowledge, only one study from SSA has examined the effect of first-line ART on lipid profile among HIV-infected patients [16] . The study conducted in Uganda found that TG levels initially decreased and then returned to baseline levels, and HDL-c levels increased substantially during the 24 months of follow-up after ART initiation. These findings are similar to our results in the current analysis. However, they did not find any association between changes in TG, HDL-c levels, and type of ART regimens. The discrepancy could be due to their substantially smaller sample size (n = 374) and different ART comparison groups. For example, they compared those who were continuously on d4T-contaning regimens with those who switched to AZT-containing regimen. Analogous analyses were conducted to compare EFV with NVP.
Our results agree with previously published reports that NVP is associated with more favorable lipid changes among patients on ART as compared to EFV. Results from the 2NN study showed that patients on NVP-based ART had larger increases in HDL-c and decreases in TC to HDL-c ratio than those on EFV-based regimens after 48 weeks of follow-up [30] . The Atlantic study showed that NVP-based ART was associated with increases in HDL-c level and a decrease in the ratio of TC to HDL-c at 24 weeks, and the positive effect was sustained at 96 weeks of treatment [29, 31] . Another study from France demonstrated that LDL-c levels decreased significantly among patients on NVP but not on EFV [14] . Similarly, a randomized controlled trial from India showed that EFV was associated with higher increase in TC compared to NVP among HIVinfected adults with tuberculosis [32] . Consistent with our study, Mankhatitham and colleagues found that the change of HDL-c value was significantly higher in the NVP group than in the EFV group among HIV patients in Thailand [33] .
In this study, we found that d4T-contaning regimens were associated with higher increases in TG levels during the 3-year follow-up compared to AZT. Because of its side effects and long-term toxicities, d4T is no longer recommended in firstline ART regimens in resource-limited settings by WHO in 2010 [34] . Many countries have implemented a plan to substitute d4T with AZT or tenofovir, but insufficient financial resources have slowed and delayed the pace of phase-out [35] . In Tanzania MDH HIV care and treatment clinics, approximately 30% of patients are still receiving first-line ART regimens containing d4T. The use of d4T has been associated with peripheral neuropathy, lactic acidosis, lipodystrophy, dyslipidemia, insulin resistance, and the development of diabetes [36] [37] [38] . Our findings support the latest WHO guideline that no longer recommends d4T for use in first-line ART in resource-limited settings.
Traditional risk factors including age, sex, and BMI might also play important roles in the lipid changes after ART initiation. Similar to findings from a previous study, we observed that adverse lipid changes were more pronounced in male patients and patients of older age [39] . Patients usually gain weight after ART initiation. We found that both BMI at baseline and BMI increase during follow-up are significant predictors for lipid changes. This finding is consistent with results from the general population.
Strengths of our study include its large sample size and relatively long follow-up. Most of the previous studies on lipid profile among HIV-infected populations were either crosssectional [11, 22] or had smaller sample sizes or shorter followup periods [14, 29, 30, 32] . To our knowledge, this is the largest longitudinal study of lipid profile to date from SSA among HIVinfected patients initiating ART. Furthermore, in order to ensure that this study population was representative of the HIV-infected population in MDH-supported clinics, we took into account the possibility of selection bias regarding lipid request by physicians by using the IPTW method in the analysis.
The limitations of this study should be noted. First, patients were not fasting at the time of lipid measurements, which may have resulted in an overestimate of dyslipidemia, especially TG levels. However, because this limitation applied to measurements at all time-points and across regimens used, the use of nonfasting measures would not have affected our inference on lipid changes over time and their associations with ART agents. In addition, researchers have showed that for the majority of people who take in an average-size meal, the overall lipid profiles will have minimal postprandial change [40] . Compared to fasting abnormal TG levels, the nonfasting abnormal TG levels might actually be more highly associated with cardiovascular disease [41] . Second, we did not collect data on diet, physical activity, smoking, or family history of cardiovascular disease, and these potential confounders could thus not be included in the analysis. Third, our findings on the lipid changes after ART initiation should be explained with caution with respect to risk of cardiovascular disease. Given the relatively young age and predominance of women in the study population, the impact of dyslipidemia may differ from that of populations with higher background cardiovascular disease. Because we did not have individual data on cardiovascular disease events, we were not able to assess the association between these lipid changes and risk of cardiovascular disease in the study population.
In summary, results from this large cohort of HIV-infected Tanzanian patients demonstrated that the prevalence of dyslipidemia is high and worsens after ART initiation, despite initial favorable changes in TG and HDL. Our results support the latest WHO guidelines that no longer recommend use of d4T as a first-line drug in resource-limited settings, and provide further evidence for HIV health professions to select lipid-friendly ART for HIV-infected patients with increased cardiovascular risk in SSA. Further studies are warranted to study the underlying mechanisms by which ART influences lipid levels, determine how much the lipid abnormalities translate into cardiovascular disease risk, and develop effective strategies to control cardiovascular risk among HIV-infected patients on ART.
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